D. Amakye, Z. Jagani, and M. Dorsch, Unraveling the therapeutic potential of the Hedgehog pathway in cancer, Nature Medicine, vol.31, issue.11, pp.1410-1422, 2013.
DOI : 10.1002/mpo.10121

M. Apte, R. Pirola, and J. Wilson, Pancreatic stellate cells: a starring role in normal and diseased pancreas, Frontiers in Physiology, vol.3, p.344, 2012.
DOI : 10.3389/fphys.2012.00344

M. Apte, J. Wilson, A. Lugea, and S. Pandol, A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment, Gastroenterology, vol.144, issue.6, pp.1210-1219, 2013.
DOI : 10.1053/j.gastro.2012.11.037

S. Arena, A. Pattarozzi, A. Massa, J. Esteve, R. Iuliano et al., An Intracellular Multi-Effector Complex Mediates Somatostatin Receptor 1 Activation of Phospho-Tyrosine Phosphatase ??, Molecular Endocrinology, vol.21, issue.1, pp.229-246, 2007.
DOI : 10.1210/me.2006-0081

R. Azar, S. Najib, H. Lahlou, C. Susini, and S. Pyronnet, Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1, Cellular and Molecular Life Sciences, vol.65, issue.19, pp.3110-3117, 2008.
DOI : 10.1007/s00018-008-8418-2

URL : https://hal.archives-ouvertes.fr/inserm-00420103

M. Bachem, E. Schneider, H. Gross, H. Weidenbach, R. Schmid et al., Identification, culture, and characterization of pancreatic stellate cells in rats and humans, Gastroenterology, vol.115, issue.2, pp.421-432, 1998.
DOI : 10.1016/S0016-5085(98)70209-4

M. Bachem, M. Schunemann, M. Ramadani, M. Siech, H. Beger et al., Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells, Gastroenterology, vol.128, issue.4, pp.907-921, 2005.
DOI : 10.1053/j.gastro.2004.12.036

G. Beatty, E. Chiorean, M. Fishman, B. Saboury, U. Teitelbaum et al., CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans, Science, vol.331, issue.6024, pp.1612-1616, 2011.
DOI : 10.1126/science.1198443

C. Bousquet, J. Guillermet-guibert, N. Saint-laurent, E. Archer-lahlou, F. Lopez et al., Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway, The EMBO Journal, vol.62, issue.17, pp.3943-3954, 2006.
DOI : 10.1128/MCB.22.12.4062-4072.2002

C. Bousquet, C. Lasfargues, M. Chalabi, S. Billah, C. Susini et al., Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.3, pp.727-737, 2012.
DOI : 10.1210/jc.2011-2088

L. Buscail, N. Saint-laurent, E. Chastre, J. Vaillant, C. Gespach et al., Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer, Cancer Res, vol.56, pp.1823-1827, 1996.

M. Chalabi, C. Duluc, P. Caron, D. Vezzosi, J. Guillermet-guibert et al., Somatostatin analogs: does pharmacology impact antitumor efficacy?, Trends in Endocrinology & Metabolism, vol.25, issue.3, pp.115-127, 2014.
DOI : 10.1016/j.tem.2013.11.003

J. Chan, D. Ryan, A. Zhu, T. Abrams, B. Wolpin et al., Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors, Endocrine Related Cancer, vol.19, issue.5, pp.615-623, 2012.
DOI : 10.1530/ERC-11-0382

D. Palma, M. Hanahan, and D. , The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities, Molecular Oncology, vol.28, issue.2, pp.111-127, 2012.
DOI : 10.1016/j.gde.2012.01.004

M. Erkan, G. Adler, M. Apte, M. Bachem, M. Buchholz et al., StellaTUM: current consensus and discussion on pancreatic stellate cell research, Gut, vol.61, issue.2, pp.172-178, 2012.
DOI : 10.1136/gutjnl-2011-301220

M. Erkan, C. Reiser-erkan, C. Michalski, B. Kong, I. Esposito et al., The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance, Current Molecular Medicine, vol.12, issue.3, pp.288-303, 2012.
DOI : 10.2174/156652412799218921

M. Erkan, Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis, The Journal of Pathology, vol.35, issue.suppl???2, 2013.
DOI : 10.1002/path.4213

C. Feig, A. Gopinathan, A. Neesse, D. Chan, N. Cook et al., The Pancreas Cancer Microenvironment, Clinical Cancer Research, vol.18, issue.16, pp.4266-4276, 2012.
DOI : 10.1158/1078-0432.CCR-11-3114

H. Friess, M. Buchler, C. Beglinger, A. Weber, J. Kunz et al., Low-Dose Octreotide Treatment Is Not Effective in Patients with Advanced Pancreatic Cancer, Pancreas, vol.8, issue.5, pp.540-545, 1993.
DOI : 10.1097/00006676-199309000-00002

F. Froeling, C. Feig, C. Chelala, R. Dobson, C. Mein et al., Retinoic Acid???Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt?????-Catenin Signaling to Slow Tumor Progression, Gastroenterology, vol.141, issue.4, pp.1486-1497, 2011.
DOI : 10.1053/j.gastro.2011.06.047

V. Heinemann, M. Reni, M. Ychou, D. Richel, T. Macarulla et al., Tumour???stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies, Cancer Treatment Reviews, vol.40, issue.1, pp.118-128, 2014.
DOI : 10.1016/j.ctrv.2013.04.004

R. Henry, T. Ciaraldi, D. Armstrong, P. Burke, M. Ligueros-saylan et al., Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.8, pp.3446-3453, 2013.
DOI : 10.1210/jc.2013-1771

M. Hidalgo, V. Hoff, and D. , Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas, Clinical Cancer Research, vol.18, issue.16, pp.4249-4256, 2012.
DOI : 10.1158/1078-0432.CCR-12-1327

S. Hingorani, E. Petricoin, A. Maitra, V. Rajapakse, C. King et al., Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse, Cancer Cell, vol.4, issue.6, pp.437-450, 2003.
DOI : 10.1016/S1535-6108(03)00309-X

R. Hwang, T. Moore, T. Arumugam, V. Ramachandran, K. Amos et al., Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression, Cancer Research, vol.68, issue.3, pp.918-926, 2008.
DOI : 10.1158/0008-5472.CAN-07-5714

M. Jacobetz, D. Chan, A. Neesse, T. Bapiro, N. Cook et al., Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer, Gut, vol.62, issue.1, pp.112-120, 2013.
DOI : 10.1136/gutjnl-2012-302529

M. Javle, R. Shroff, H. Xiong, G. Varadhachary, D. Fogelman et al., Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies, BMC Cancer, vol.68, issue.1, p.368, 2010.
DOI : 10.1158/0008-5472.CAN-07-6720

S. Kozono, K. Ohuchida, D. Eguchi, N. Ikenaga, K. Fujiwara et al., Pirfenidone Inhibits Pancreatic Cancer Desmoplasia by Regulating Stellate Cells, Cancer Research, vol.73, issue.7, pp.2345-2356, 2013.
DOI : 10.1158/0008-5472.CAN-12-3180

H. Laklai, S. Laval, L. Dumartin, P. Rochaix, M. Hagedorn et al., Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer, Proceedings of the National Academy of Sciences, vol.106, issue.42, pp.17769-17774, 2009.
DOI : 10.1073/pnas.0908674106

URL : https://hal.archives-ouvertes.fr/inserm-00504705

C. Lasfargues, Y. Martineau, C. Bousquet, and S. Pyronnet, Changes in Translational Control after Pro-Apoptotic Stress, International Journal of Molecular Sciences, vol.14, issue.1, pp.177-190, 2012.
DOI : 10.3390/ijms14010177

S. Laval, H. Laklai, M. Fanjul, M. Pucelle, H. Laurell et al., Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides, Oncogene, vol.56, issue.15, pp.1934-1944, 2014.
DOI : 10.1242/jcs.085480

M. Lesina, S. Wormann, P. Neuhofer, L. Song, and H. Algul, Interleukin-6 in inflammatory and malignant diseases of the pancreas, Seminars in Immunology, vol.26, issue.1, pp.80-87, 2014.
DOI : 10.1016/j.smim.2014.01.002

T. Mace, Z. Ameen, A. Collins, S. Wojcik, M. Mair et al., Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner, Cancer Research, vol.73, issue.10, pp.3007-3018, 2013.
DOI : 10.1158/0008-5472.CAN-12-4601

Y. Martineau, R. Azar, C. Bousquet, and S. Pyronnet, Anti-oncogenic potential of the eIF4E-binding proteins, Oncogene, vol.336, issue.6, pp.671-677, 2013.
DOI : 10.1038/nrclinonc.2011.16

Y. Martineau, R. Azar, D. Muller, C. Lasfargues, E. Khawand et al., Pancreatic tumours escape from translational control through 4E-BP1 loss, Oncogene, vol.136, issue.11, pp.1363-1374, 2014.
DOI : 10.1371/journal.pone.0000242

E. Mathew, Y. Zhang, A. Holtz, K. Kane, J. Song et al., Dosage-Dependent Regulation of Pancreatic Cancer Growth and Angiogenesis by Hedgehog Signaling, Cell Reports, vol.9, issue.2, pp.484-494, 2014.
DOI : 10.1016/j.celrep.2014.09.010

J. Mccarroll, P. Phillips, R. Kumar, S. Park, R. Pirola et al., Pancreatic stellate cell migration: role of the phosphatidylinositol 3-kinase (PI3-kinase) pathway, Biochemical Pharmacology, vol.67, issue.6, pp.1215-1225, 2004.
DOI : 10.1016/j.bcp.2003.11.013

M. Meads, R. Gatenby, and W. Dalton, Environment-mediated drug resistance: a major contributor to minimal residual disease, Nature Reviews Cancer, vol.112, issue.9, pp.665-674, 2009.
DOI : 10.1038/nrc2714

S. Mitsunaga, M. Ikeda, S. Shimizu, I. Ohno, J. Furuse et al., Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer, 2013.

S. Najib, N. Saint-laurent, J. Esteve, S. Schulz, E. Boutet-robinet et al., A Switch of G Protein-Coupled Receptor Binding Preference from Phosphoinositide 3-Kinase (PI3K)-p85 to Filamin A Negatively Controls the PI3K Pathway, Molecular and Cellular Biology, vol.32, issue.5, pp.1004-1016, 2012.
DOI : 10.1128/MCB.06252-11

K. Olive, M. Jacobetz, C. Davidson, A. Gopinathan, D. Mcintyre et al., Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer, Science, vol.324, issue.5933, pp.1457-1461, 2009.
DOI : 10.1126/science.1171362

B. Ozdemir, T. Pentcheva-hoang, J. Carstens, X. Zheng, C. Wu et al., Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival, Cancer Cell, vol.25, issue.6, pp.719-734, 2014.
DOI : 10.1016/j.ccr.2014.04.005

P. Perez-mancera, C. Guerra, M. Barbacid, and D. Tuveson, What We Have Learned About Pancreatic Cancer From Mouse Models, Gastroenterology, vol.142, issue.5, pp.1079-1092, 2012.
DOI : 10.1053/j.gastro.2012.03.002

P. Provenzano, C. Cuevas, A. Chang, V. Goel, V. Hoff et al., Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma, Cancer Cell, vol.21, issue.3, pp.418-429, 2012.
DOI : 10.1016/j.ccr.2012.01.007

A. Rhim, P. Oberstein, D. Thomas, E. Mirek, C. Palermo et al., Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma, Cancer Cell, vol.25, issue.6, pp.735-747, 2014.
DOI : 10.1016/j.ccr.2014.04.021

H. Schmid, Pasireotide (SOM230): Development, mechanism of action and potential applications, Molecular and Cellular Endocrinology, vol.286, issue.1-2, pp.69-74, 2008.
DOI : 10.1016/j.mce.2007.09.006

E. Schmidt, G. Clavarino, M. Ceppi, and P. Pierre, SUnSET, a nonradioactive method to monitor protein synthesis, Nature Methods, vol.178, issue.4, pp.275-277, 2009.
DOI : 10.1016/j.neuron.2005.01.015

URL : https://hal.archives-ouvertes.fr/hal-00408410

M. Sherman, R. Yu, D. Engle, N. Ding, A. Atkins et al., Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy, Cell, vol.159, issue.1, pp.80-93, 2014.
DOI : 10.1016/j.cell.2014.08.007

F. Sicard, M. Gayral, H. Lulka, L. Buscail, and P. Cordelier, Targeting miR-21 for the Therapy of Pancreatic Cancer, Molecular Therapy, vol.21, issue.5, pp.986-994, 2013.
DOI : 10.1038/mt.2013.35

M. Singh, A. Lima, R. Molina, P. Hamilton, A. Clermont et al., Assessing therapeutic The Authors EMBO Molecular Medicine Anti-stromal-targeted therapy Camille Duluc et al responses in Kras mutant cancers using genetically engineered mouse models, EMBO Molecular Medicine Nat Biotechnol, vol.7, issue.28, pp.585-593, 2010.

V. Hoff, D. Ramanathan, R. Borad, M. Laheru, D. Smith et al., -Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial, Journal of Clinical Oncology, vol.29, issue.34, pp.4548-4554, 2011.
DOI : 10.1200/JCO.2011.36.5742

URL : https://hal.archives-ouvertes.fr/hal-00261277

A. Vonlaufen, S. Joshi, C. Qu, P. Phillips, Z. Xu et al., Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer Cells, Cancer Research, vol.68, issue.7, pp.2085-2093, 2008.
DOI : 10.1158/0008-5472.CAN-07-2477

B. Wolpin, A. Hezel, T. Abrams, L. Blaszkowsky, J. Meyerhardt et al., Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer, Journal of Clinical Oncology, vol.27, issue.2, pp.193-198, 2009.
DOI : 10.1200/JCO.2008.18.9514

Y. Xiao, R. Jaskula-sztul, A. Javadi, W. Xu, J. Eide et al., Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy, Nanoscale, vol.281, issue.22, pp.7185-7193, 2012.
DOI : 10.1039/c2nr31853a